Immuron Stock Explodes; Plus, the Small-Cap Expected to Double

Kerrisdale Capital said the prognosis for CDNA stock is dim

Jul 16, 2019 at 3:25 PM
facebook X logo linkedin

U.S. stocks are flat today, though the Dow managed a fresh record high. Looking at the healthcare sector specifically, three names making big moves are Immuron Limited (NASDAQ:IMRN), Bio-Path Holdings Inc (NASDAQ:BPTH), and CareDx Inc (NASDAQ:CDNA). Here's what to know about the shares of IMRN, BPTH, and CDNA today.

Podcast Mentions Send Consumers to Immuron's Travelan

After jumping roughly 150% earlier, the shares of Australia-based IMRN were last seen 64% higher at $4.81. Sparking the breakout was the company's announcement that podcast mentions helped boost sales of its Travelan product, which is meant to reduce diarrhea and other digestion issues when traveling to foreign countries. Overall, total North American revenue jumped by 52% in the company's fiscal year 2019. On the other hand, the stock has still given back more than half its value in the past year, and hit an all-time low of $2.38 in June.

New "Buy" Rating, Lofty Price Target Lift BPTH

BPTH stock is trading up 17.4% at $15.15, after H.C. Wainwright began coverage with a "buy" recommendation and $28 price target -- a premium of 117% to yesterday's close. The brokerage firm cited confidence in the company's main product, prexigebersen, and Bio-Path's DNAbilize technology. While BPTH is set to settle atop the 50-day moving average for the first time since April, the shares remain stuck in their series of lower highs from recent months, though pullbacks have been contained by the 200-day moving average. There was only one brokerage firm in coverage before today, though it also recommended buying the cancer treatment specialist.

Scathing Short Position Smacks CareDx

CDNA shares, meanwhile, are moving sharply lower, last seen 14.2% below breakeven at $32.01 -- set for their worst session since July 2017. A new short position out of Kerrisdale Capital is responsible for the sell-off, with the firm saying CareDx's diagnostic test AlloSure "is mostly useless, and potentially dangerous if used improperly." Kerrisdale said CareDX will be "in a precarious position, particularly as physicians wise up to the futility of AlloSure," and Medicare coverage will become jeopardized. As such, "the prognosis for [CDNA] stock price is dim."

Despite the huge pullback, the stock remains up 166% year-over-year, having just touched an all-time high of $41.27 on July 11. Looking at the data, Kerrisdale is far from the only CDNA bear. Short interest increased 14% in the last reporting period, and now accounts for 13.7% of the equity's total available float. Today, of course, the stock has landed on the short-sale restricted list.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI